BIM Stock Overview
Develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
bioMérieux S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €103.40 |
52 Week High | €108.90 |
52 Week Low | €84.54 |
Beta | 0.19 |
11 Month Change | 5.51% |
3 Month Change | 9.82% |
1 Year Change | 7.53% |
33 Year Change | -2.50% |
5 Year Change | 38.98% |
Change since IPO | 934.00% |
Recent News & Updates
Return Trends At bioMérieux (EPA:BIM) Aren't Appealing
Aug 03bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
May 30Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)
Apr 18Recent updates
Return Trends At bioMérieux (EPA:BIM) Aren't Appealing
Aug 03bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
May 30Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)
Apr 18bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings
Mar 31bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 17These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Mar 15bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
Jan 27bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward
Jan 06A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Dec 16These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Oct 23bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger
Oct 05There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings
Sep 15Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Sep 07Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?
Jun 30Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down
Jun 09Is bioMérieux (EPA:BIM) Using Too Much Debt?
Mar 31The Return Trends At bioMérieux (EPA:BIM) Look Promising
Feb 23Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?
Jan 27bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet
Dec 16bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth
Oct 18Is bioMérieux (EPA:BIM) Using Too Much Debt?
Sep 14Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital
Aug 11An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued
Jul 23Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?
Jul 05bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85
May 26Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns
May 11bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year
Apr 23bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85
Apr 09bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85
Mar 25Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?
Mar 13I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease
Feb 08Why We Like The Returns At bioMérieux (EPA:BIM)
Dec 21Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Dec 07Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching
Nov 07Is bioMérieux (EPA:BIM) A Risky Investment?
Oct 07Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital
Sep 22Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)
Sep 07Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today
Aug 06There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital
Jun 15A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)
May 31Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today
Apr 30bioMérieux (EPA:BIM) Could Easily Take On More Debt
Mar 28The Trend Of High Returns At bioMérieux (EPA:BIM) Has Us Very Interested
Mar 13Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Feb 25If You Had Bought bioMérieux (EPA:BIM) Shares Five Years Ago You'd Have Earned 237% Returns
Feb 09If You Like EPS Growth Then Check Out bioMérieux (EPA:BIM) Before It's Too Late
Jan 20Could The Market Be Wrong About bioMérieux S.A. (EPA:BIM) Given Its Attractive Financial Prospects?
Dec 30These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Dec 17Has bioMérieux (EPA:BIM) Got What It Takes To Become A Multi-Bagger?
Dec 03Shareholder Returns
BIM | FR Medical Equipment | FR Market | |
---|---|---|---|
7D | 4.3% | 1.6% | 1.4% |
1Y | 7.5% | 21.3% | 0.9% |
Return vs Industry: BIM underperformed the French Medical Equipment industry which returned 21.3% over the past year.
Return vs Market: BIM exceeded the French Market which returned 1.7% over the past year.
Price Volatility
BIM volatility | |
---|---|
BIM Average Weekly Movement | 3.0% |
Medical Equipment Industry Average Movement | 5.4% |
Market Average Movement | 5.0% |
10% most volatile stocks in FR Market | 9.8% |
10% least volatile stocks in FR Market | 2.6% |
Stable Share Price: BIM has not had significant price volatility in the past 3 months.
Volatility Over Time: BIM's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1963 | 13,696 | Pierre Boulud | www.biomerieux.com |
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests.
bioMérieux S.A. Fundamentals Summary
BIM fundamental statistics | |
---|---|
Market cap | €12.22b |
Earnings (TTM) | €357.60m |
Revenue (TTM) | €3.67b |
34.2x
P/E Ratio3.3x
P/S RatioIs BIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIM income statement (TTM) | |
---|---|
Revenue | €3.67b |
Cost of Revenue | €1.62b |
Gross Profit | €2.06b |
Other Expenses | €1.70b |
Earnings | €357.60m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 05, 2024
Earnings per share (EPS) | 3.03 |
Gross Margin | 55.99% |
Net Profit Margin | 9.73% |
Debt/Equity Ratio | 9.9% |
How did BIM perform over the long term?
See historical performance and comparison